The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated
